<DOC>
	<DOCNO>NCT02270424</DOCNO>
	<brief_summary>The aim study compare effectiveness two treatment severe / severe COPD patient : one , conventional medicine base 2013 Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Chinese Treatment Guidelines ; , TCM treatments conventional medicine , evaluate certain effect .</brief_summary>
	<brief_title>Effect Traditional Chinese Medicine Outcomes Patients With Severe / Very Severe COPD</brief_title>
	<detailed_description>Patients severe severe COPD likely suffer repeat exacerbation rapidly decline lung function generate increase risk death time COPD related hospitalization . Although many therapy exist develop relieve symptom reduce mortality COPD , study moderate severe COPD . There clinical trial compare therapeutic alternative severe sever COPD . Furthermore , randomize control trial comprehensive Traditional Chinese medicine ( TCM ) intervention , especially base TCM pattern , certain evidence show definite effect COPD patient . In addition , study effect TCM outcomes mild moderate COPD patient progress carry December 2014 ( NCT01486186 ) . Hence , correspond mild moderate COPD patient , The study aim evaluate effectiveness TCM severe / severe COPD patient . This multi-center , randomize , double-blind , control study evaluate effectiveness TCM severe / Severe COPD patient . Following 14 day run-in period , approximately 564 subject randomly assign conventional medicine treatment group , TCM conventional medicine treatment group 52 week . After 52 week treatment period , subject two treatment arm follow-up 52 week . The primary outcome measure frequency exacerbation . The secondary efficacy measure include all-cause mortality , FEV1 , dyspnea ( MMRC ) , exercise capacity ( 6MWD ) , quality life ( CAT , SF-36 COPD-PRO ) , effectiveness satisfaction treatment ( ESQ-COPD ) . Safety assess collection adverse event . There total 9 study visit ( baseline , 13 , 26 , 39 52 week treatment , 13 , 26 , 39 52 week follow-up ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>A confirmed diagnosis severe severe COPD . medically stable Age 40 80 year . Syndrome differentiation belong syndrome deficiency pulmonosplenic qi , syndrome insufficiency qi lung kidney , syndrome insufficiency qi yin lung kidney . twoweek washout period prior randomization Without participation interventional trial previous one month . With informed consent sign . Pregnant breastfeed woman . Any psychiatric condition render patient unable understand nature , scope possible consequence study . Current respiratory disorder COPD ( e.g. , bronchiectasis , bronchial asthma , tuberculosis , lung fibrosis , pulmonary thromboembolic , diffuse panbronchiolitis ) . Complicated neuromuscular disorder , affected respiration . Complicated heart failure ( NYHA Class III IV ) , myocardial infarction within six month , unstable hemodynamics . Complicated malignancy , congenital acquire immune deficiency . Complicated serious hepatic renal disease ( liver cirrhosis , portal hypertension , bleed varicose vein , dialysis , renal transplantation ) . Participating trial allergic use medicine .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Pulmonary Disease , Chronic Obstructive</keyword>
	<keyword>Medicine , Chinese Traditional</keyword>
	<keyword>Humans</keyword>
	<keyword>Treatment Outcome</keyword>
</DOC>